The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.
 
Robert J. Kreitman
Employment - Regional Cancer Care Associates
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Novartis (Inst); Teva (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor on the NIH patent for Moxetumomab Pasudotox, receives partial patent royalties from NIH
 
Maryalice Stetler-Stevenson
No Relationships to Disclose
 
Constance Yuan
No Relationships to Disclose
 
Hao-Wei Wang
No Relationships to Disclose
 
Hong Zhou
No Relationships to Disclose
 
Mark Raffeld
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer
 
Liqiang Xi
No Relationships to Disclose
 
Evgeny Arons
No Relationships to Disclose
 
Julie Feurtado
No Relationships to Disclose
 
Lacey James-Echenique
No Relationships to Disclose
 
Raul Braylan
No Relationships to Disclose
 
Katherine R. Calvo
No Relationships to Disclose
 
Irina Maric
No Relationships to Disclose
 
Alina Dulau
No Relationships to Disclose
 
Ira Pastan
Patents, Royalties, Other Intellectual Property - NIH/NCI patent for Moxe